News & Updates

Show Multimedia Only

Sexual dysfunction prevalent in breast cancer survivors

23 Feb 2026

Breast cancer survivors often experience female sexual dysfunction (FSD), which is significantly associated with disease-related factors and the lack of sexual counselling, reports a study.

Sexual dysfunction prevalent in breast cancer survivors

23 Feb 2026

3D printing enables personalization, dosing precision of ondansetron HCl dihydrate

20 Feb 2026 by

A recent study has shown the effectiveness and precision of semi-solid extrusion (SSE) 3D printing in producing various formulations of ondansetron HCl dihydrate in hospital pharmacies.

3D printing enables personalization, dosing precision of ondansetron HCl dihydrate

20 Feb 2026

Lower tolerated dose of adjuvant capecitabine seen in several TNBC patients

20 Feb 2026

Many patients with triple-negative breast cancer (TNBC) have a lower tolerated dose of capecitabine relative to the recommended adjuvant dose, a study has shown.

Lower tolerated dose of adjuvant capecitabine seen in several TNBC patients

20 Feb 2026

Predictive model spots genes linked to more aggressive ATC

18 Feb 2026

A new genomic predictive model has identified mutated genes that are associated with the most aggressive anaplastic thyroid cancer (ATC), according to a study.

Predictive model spots genes linked to more aggressive ATC

18 Feb 2026

Ultraprocessed foods are the new cigarettes: study

17 Feb 2026 by

Ultraprocessed foods (UPFs) are associated with several preventable diseases and must be viewed not only through a nutritional lens but also as addictive, industrially engineered substances, which can be likened to cigarettes, suggests a recent study.

Ultraprocessed foods are the new cigarettes: study

17 Feb 2026

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

11 Feb 2026 by

Patients with potentially resectable hepatocellular carcinoma (HCC) may receive neoadjuvant nivolumab plus ipilimumab therapy, followed by surgery, to improve their survival, suggests a study.

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

11 Feb 2026

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

08 Feb 2026

Treatment with the combination of savolitinib plus osimertinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) harbouring EGFR mutation and MET amplification, as shown in the phase III SACHI trial.

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

08 Feb 2026

GLP-1RA bests aspirin for CRC prevention

06 Feb 2026 by

Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) appears to confer greater protection against the development of colorectal cancer (CRC) as compared with aspirin, according to a retrospective study.

GLP-1RA bests aspirin for CRC prevention

06 Feb 2026

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

06 Feb 2026 by

Treatment with zanidatamab combined with tislelizumab and/or chemotherapy (CT) significantly improves progression-free survival (PFS) in patients with HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA), as shown in the primary analysis from HERIZON-GEA-01.

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

06 Feb 2026

$Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma$

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma

06 Feb 2026

In the treatment of patients with relapsed or refractory follicular lymphoma, adding tafasitamab to lenalidomide and rituximab appears to improve progression-free survival (PFS) while having an acceptable safety profile, according to the phase III inMIND study.

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma

06 Feb 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

Sexual dysfunction prevalent in breast cancer survivors

Sexual dysfunction prevalent in breast cancer survivors

3D printing enables personalization, dosing precision of ondansetron HCl dihydrate

3D printing enables personalization, dosing precision of ondansetron HCl dihydrate

Lower tolerated dose of adjuvant capecitabine seen in several TNBC patients

Lower tolerated dose of adjuvant capecitabine seen in several TNBC patients

Predictive model spots genes linked to more aggressive ATC

Predictive model spots genes linked to more aggressive ATC

Ultraprocessed foods are the new cigarettes: study

Ultraprocessed foods are the new cigarettes: study

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

GLP-1RA bests aspirin for CRC prevention

GLP-1RA bests aspirin for CRC prevention

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma